Skip to main content
Gan & Lee Pharmaceuticals. logo

Gan & Lee Pharmaceuticals. — Investor Relations & Filings

Ticker · 603087 ISIN · CNE100003ZH1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 874 across all filing types
Latest filing 2026-04-22 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603087

About Gan & Lee Pharmaceuticals.

https://www.ganlee.com/

Gan & Lee Pharmaceuticals is a biopharmaceutical company specializing in the research, development, production, and commercialization of insulin analogs and medical devices. The company focuses on diabetes care, offering a comprehensive portfolio that includes insulin glargine, insulin lispro, and insulin aspart, alongside delivery systems such as reusable and disposable insulin pens. Beyond its core expertise in metabolic disorders, the firm is expanding its research pipeline into oncology, cardiovascular diseases, and autoimmune conditions. Utilizing advanced recombinant DNA technology, the company maintains vertically integrated manufacturing capabilities to ensure high-quality therapeutic solutions. Its products are distributed across global markets, aiming to improve the quality of life for patients requiring long-term endocrine management.

Recent filings

Filing Released Lang Actions
第五届董事会第八次会议决议公告
Regulatory Filings Classification · 62% confidence The document is a Chinese ‘董事会会议决议公告’ – a full board resolution announcement detailing meeting procedures, voting outcomes, and multiple governance proposals. It is not an earnings release, capital update, audit report, or annual/interim report. It does not announce changes in directors or senior management positions, nor is it simply pointing to an external report. Since there is no specific category for board resolutions, it falls under the general regulatory announcements fallback.
2026-04-22 Chinese
关于公司2024年限制性股票激励计划第二个解除限售期解除限售条件成就的公告
Share Issue/Capital Change Classification · 75% confidence The document is a corporate announcement by 甘李药业股份有限公司 concerning the achievement of conditions and the scheduled unlocking (release from restriction) of shares under its 2024 restricted stock incentive plan. It is not an earnings release, management change, or regulatory filing announcing publication of a report. It relates directly to a corporate equity event affecting the company’s share capital (the release of restricted shares into tradable capital). Among the defined categories, “Share Issue/Capital Change” (SHA) best captures this type of notice regarding changes to share capital restrictions and issuance conditions.
2026-04-22 Chinese
关于公司2025年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement by the Board of 甘李药业 for the 2025 fiscal year profit distribution plan, specifying per-share dividend, aggregate amount, record date conditions, and board/shareholder approval steps. This corresponds to an official dividend notice rather than a full annual or interim report. It clearly outlines the dividend amount and payment details for shareholders.
2026-04-22 Chinese
关于回购注销部分限制性股票并调整回购价格的公告
Transaction in Own Shares Classification · 95% confidence The document is a corporate announcement (“公告”) from 甘李药业股份有限公司 detailing the board’s approval to repurchase and cancel restricted stock under its 2022 and 2024 incentive plans, specifying quantities, prices, funding source and legal opinions. This is a share repurchase transaction (the company buying back its own shares). Therefore, it clearly falls under Transaction in Own Shares (POS).
2026-04-22 Chinese
关于2025年度“提质增效重回报”行动方案评估报告暨2026年度“提质增效重回报”行动方案的公告
Regulatory Filings Classification · 78% confidence The document is a Chinese stock exchange announcement (“公告”) by 甘李药业股份有限公司 reporting on its 2025 “提质增效重回报” action plan evaluation and outlining the 2026 action plan. It is not an AGM presentation, earnings release, financial report, share issue, proxy, or any other narrowly defined category. It provides a management evaluation and future plan in compliance with Shanghai Stock Exchange initiatives, which does not fit any specific type except a general regulatory filing. Therefore, it should be classified under the fallback category Regulatory Filings (RNS).
2026-04-22 Chinese
关于公司部分募投项目延期的公告
Regulatory Filings Classification · 62% confidence The document is a formal announcement by 甘李药业股份有限公司’s board regarding the postponement of part of its previously raised funds investment projects (“募投项目延期”). It details the use of IPO proceeds, cumulative investments, and justifications for delaying the completion dates of specific fundraising‐backed projects. It is not a new financing or capital‐structure change, nor an earnings release, dividend notice, or management discussion. It is a regulatory disclosure that does not fit any of the more specific categories, so it falls under the general Regulatory Filings (RNS) category.
2026-04-22 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.